skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

11971

Cancer biomarker HER-2/neu in breast cancer in Indian women



Original Research

(4640) Total Article Views


Authors: Singhai R, Patil VW, Patil AV

Published Date March 2011 Volume 2011:3 Pages 21 - 26
DOI: http://dx.doi.org/10.2147/BCTT.S17108

Rajeev Singhai1, Amit V Patil2, Vinayak W Patil1
1Department of Biochemistry, Grant Medical College and Sir J J Group of Hospitals, Mumbai, India; 2Department of General Surgery, Government Medical College, Miraj, Maharashtra, India

Aim and objectives: In Indian women with breast cancer, the HER-2/neu gene is amplified in 30% of cases. Elevated serum HER-2/neu levels have been shown to be associated with a poor clinical prognosis and decreased survival in early stage breast cancer patients, and testing for this may help to manage the disease. The present study was therefore to estimate serum HER-2/neu levels in breast cancer patients and associate these with other prognostic factors.
Materials and methods: Serum HER-2/neu levels were studied in 207 patients with breast cancer, 15 with benign breast diseases, (BBD) and 175 age-matched healthy controls. Patients' age, menopausal status, node, and estrogen receptor (ER) and progesterone receptor (PgR) status were compared with serum HER-2/neu levels.
Results: Serum HER-2/neu overexpression was associated with age, disease stage and positive nodal status but not with menopausal status. Serum HER-2/neu levels were negatively correlated with hormone receptor positivity.
Conclusion: HER-2/neu serum tests should be done more frequently in Indian women with breast cancer, irrespective of their ER and PgR hormone receptor status. ELISA is a reliable and economical tool to assess the HER-2/neu status in tumors, when breast tissue samples are not available.

Keywords: breast cancer, serum HER-2/neu receptor assay, hormone receptor, ER, PgR

This paper has been retracted.


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr Rajeev Singhai


Readers of this article also read:
  • ASCO 2013 Meet the Editor

    We invite you to meet Prof Dr Hans-Joachim Schmoll at the Dove Medical Press booth 22102 on June 1st at 11am. Prof Dr Schmoll is the Editor-in-Chief of the journal OncoTargets and Therapy (IF 1.26).